Fosun Pharmaceutical announced that Fosun Kerry Biotechnology Co., Ltd., a holding subsidiary of the company, initiated a phase II clinical trial on FKC516 injection for recurrent or refractory B-cell non-Hodgkin lymphoma in China. FKC516 is a targeted CD20 autologous CAR-T cell therapy product introduced under the company's license. The company has exclusive rights to develop and commercialize this product in all disease fields around the world. As of September 2026, the company's cumulative R&D investment for FKC516 at this stage is about 13.37 million yuan. As of the announcement date, no CAR-T products with the same target have been approved for marketing in China. The product still needs to be clinically tested and approved before it can be marketed, so there is uncertainty.

Fosun Pharmaceuticals announced that Fosun Kerry Biotechnology Co., Ltd., a holding subsidiary of the company, initiated a phase II clinical trial on FKC516 injection for recurrent or refractory B-cell non-Hodgkin lymphoma in China. FKC516 is a targeted CD20 autologous CAR-T cell therapy product introduced under the company's license. The company has exclusive rights to develop and commercialize this product in all disease fields around the world. As of September 2026, the company's cumulative R&D investment for FKC516 at this stage is about 13.37 million yuan. As of the announcement date, no CAR-T products with the same target have been approved for marketing in China. The product still needs to be clinically tested and approved before it can be marketed, so there is uncertainty.